Evidence map›Paper›PMID 24625552›Full record

ArticleLeukemia2014

Immunophenotypic alterations of bone marrow myeloid cell compartments in multiple myeloma patients predict for myelodysplasia-associated cytogenetic alterations.

S Matarraz, B Paiva, M Díez-Campelo, S Bárrena, M Jara-Acevedo, M L Gutiérrez, J M Sayagués, M-L Sánchez, P Bárcena, M P Garrastazul and 11 more

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Leukemia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Second malignancies in multiple myeloma; emerging patterns and future directions.Best practice & research. Clinical haematology · 2020
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

S MatarrazDepartment of Medicine, Centro de Investigación del Cáncer (IBMCC, University of Salamanca-CSIC) and IBSAL, Salamanca, Spain.
B PaivaClínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain.
M Díez-CampeloDepartment of Hematology, University Hospital, IBSAL and University of Salamanca, Salamanca, Spain.
S BárrenaDepartment of Medicine, Centro de Investigación del Cáncer (IBMCC, University of Salamanca-CSIC) and IBSAL, Salamanca, Spain.
M Jara-AcevedoDepartment of Medicine, Centro de Investigación del Cáncer (IBMCC, University of Salamanca-CSIC) and IBSAL, Salamanca, Spain.
M L GutiérrezDepartment of Medicine, Centro de Investigación del Cáncer (IBMCC, University of Salamanca-CSIC) and IBSAL, Salamanca, Spain.
J M SayaguésDepartment of Medicine, Centro de Investigación del Cáncer (IBMCC, University of Salamanca-CSIC) and IBSAL, Salamanca, Spain.
M-L SánchezDepartment of Medicine, Centro de Investigación del Cáncer (IBMCC, University of Salamanca-CSIC) and IBSAL, Salamanca, Spain.
P BárcenaDepartment of Medicine, Centro de Investigación del Cáncer (IBMCC, University of Salamanca-CSIC) and IBSAL, Salamanca, Spain.
M P GarrastazulDepartment of Hematology, Hospital Punta Europa, Algeciras, Spain.
M J BerruezoDepartment of Hematology, Hospital Punta Europa, Algeciras, Spain.
J M DuranDepartment of Hematology, Hospital La Línea, Cádiz, Spain.
C CerveróDepartment of Hematology, Hospital Virgen de la Luz, Cuenca, Spain.
J A García-ErceDepartment of Hematology, Hospital San Jorge, Huesca, Spain.
L FlorensaDepartment of Hematology, Hospital del Mar, Barcelona, Spain.
G D MéndezDepartment of Hematology, Hospital de Jerez, Cádiz, Spain.
O GutierrezDepartment of Hematology, Rio Hortega Hospital, Valladolid, Spain.
M C Del CañizoDepartment of Hematology, University Hospital, IBSAL and University of Salamanca, Salamanca, Spain.
J J M van DongenDepartment of Immunology, Erasmus Medical Center, Rotterdam, The Netherlands.
J F San MiguelClínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain.
A OrfaoDepartment of Medicine, Centro de Investigación del Cáncer (IBMCC, University of Salamanca-CSIC) and IBSAL, Salamanca, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Bone Marrow CellsChromosome AberrationsHumansImmunophenotypingMultiple MyelomaMyelodysplastic SyndromesMyeloid Cells

Identifiers

PMID24625552

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.